Clinical Trial

Ticagrelore Alone Post PCI

Study acronym: TICALONE
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-15; most recent amendment 2025-05-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-16
Trial Details
NCT Number NCT06509893
Lead Sponsor Shiraz University of Medical Sciences
Conditions Coronary Artery Disease
Enrollment 5,400 participants
Start Date 2024-08-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-21